Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALXN1210 (Ultomiris) MAD Study in Healthy Volunteers
NCT05288673Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2015
- Primary completion
- Sep 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ravulizumab in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) (3 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events. Started Jul 2015; status: completed.
02
Drugs
ravulizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on NCT05288673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05288673.